In Europe, the first gene therapy drug recommended for commercial approval named Gylbera, was an adenoviral vector used for restoring lipoprotein lipase expression for the treatment of lipoprotein lipase (LPL) deficiency [22]. Here, LPL is linked to hyperinsulinemic hypoglycemia, familial, 4.